CIP
ACOR

Convergence Investment Partners’s Acorda Therapeutics ACOR Stock Holding History

Convergence Investment Partners’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-137
Closed -$219K – 399
2019
Q1 		$219K Sell
137
-9
-6% -$16.2K 0.05% 264
2018
Q4 		$274K Buy
+146
New +$318K 0.06% 264
2018
Q2 		– Sell
-425
Closed -$1.21M – 959
2018
Q1 		$1.21M Hold
425
– – 0.16% 208
2017
Q4 		$1.09M Sell
425
-31
-7% -$88.1K 0.15% 235
2017
Q3 		$1.29M Buy
+456
New +$1.2M 0.18% 209
2016
Q3 		– Sell
-168
Closed -$514K – 400
2016
Q2 		$514K Buy
+168
New +$546K 0.07% 279

Other funds holding ACOR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Convergence Investment Partners's ACOR Position: Q2 2019 in Review

Convergence Investment Partners sold out of Acorda Therapeutics (ACOR) in Q2 2019, closing a stake of 137 shares — an estimated $219K sold.

Convergence Investment Partners first reported a position in ACOR in Q2 2016 and held it in 6 quarters. The position peaked at $1.29M in Q3 2017. 163 funds tracked by Wall St. Rank hold ACOR as of Q2 2019.

  • Convergence Investment Partners reported no remaining Acorda Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Convergence Investment Partners sold 137 Acorda Therapeutics shares in Q2 2019, an estimated $219K.
  • Convergence Investment Partners first reported a position in Acorda Therapeutics in Q2 2016 and held it in 6 quarters.
  • Convergence Investment Partners's Acorda Therapeutics position peaked at $1.29M in Q3 2017.
  • 163 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q2 2019.

Based on Convergence Investment Partners's 13F filing for Q2 2019, filed 23 Jul 2019.